Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade
10:55am, Friday, 07'th Mar 2025
The mean of analysts' price targets for ANI (ANIP) points to a 32.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Thursday, 06'th Mar 2025
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
01:06pm, Thursday, 06'th Mar 2025
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
10:45am, Wednesday, 05'th Mar 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
10:41am, Wednesday, 05'th Mar 2025
Here is how ANI Pharmaceuticals (ANIP) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
04:30pm, Monday, 03'rd Mar 2025
PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified Cortrophi
ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
05:45pm, Friday, 28'th Feb 2025
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & D
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
10:37am, Friday, 28'th Feb 2025
On Friday, ANI Pharmaceuticals Inc ANIP reported fourth-quarter adjusted EPS of $1.63, up from $1 a year ago, beating the consensus of $1.44.
ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Friday, 28'th Feb 2025
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street e
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
06:50am, Friday, 28'th Feb 2025
BAUDETTE, Minn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March
04:30pm, Wednesday, 19'th Feb 2025
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer,
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
04:05pm, Tuesday, 18'th Feb 2025
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full y
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
10:46am, Monday, 17'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
10:41am, Monday, 17'th Feb 2025
Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year.
ANI Pharmaceuticals: More Than Just A Generics Company
09:08am, Tuesday, 11'th Feb 2025
ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growt
